科技股大涨。 A股市场今天（10月24日）上午整体进一步上行，其中上证指数盘中再创近10年新高，创业板指、科创50指数走势强劲。盘面 上，科技股整体大涨，成为上午市场最大亮点之一。 热点个股方面，被一些网民称为"易中天""纪连海"的几只典型热门股再度上行。 沪指盘中再创近10年新高 A股市场今天上午整体进一步上行，其中上证指数盘中突破年内高点，并再创近10年新高。截至中午收盘，上证指数上涨0.42%， 深证成指上涨1.3%，创业板指上涨2.09%，科创50指数上涨2.98%。 科创板表现抢眼，表征科创板表现的科创50指数大涨，盘中涨幅一度超过3%。 招股资料显示，超颖电子主营业务是印制电路板的研发、生产和销售，公司产品广泛应用于汽车电子、显示、储存、消费电子、 通信等领域，产品涵盖双面板至二十六层板、HDI板、厚铜板、金属基板、高频高速板等。 招股资料称，截至报告期期末，公司共取得14项发明专利和85项实用新型专利。经过多年的发展，公司获得"湖北省支柱产业细 分领域隐形冠军培育企业""湖北省智能制造示范单位""湖北省级重点项目""江苏省毫米波雷达板工程技术研究中心""苏州市汽车 高频雷达材料工程技术研究中心" ...

科技股大涨。 A股市场今天（10月24日）上午整体进一步上行，其中上证指数盘中再创近10年新高，创业板指、科创 50指数走势强劲。盘面上，科技股整体大涨，成为上午市场最大亮点之一。 热点个股方面，被一些网民称为"易中天""纪连海"的几只典型热门股再度上行。 沪指盘中再创近10年新高 A股市场今天上午整体进一步上行，其中上证指数盘中突破年内高点，并再创近10年新高。截至中午收 盘，上证指数上涨0.42%，深证成指上涨1.3%，创业板指上涨2.09%，科创50指数上涨2.98%。 科创板表现抢眼，表征科创板表现的科创50指数大涨，盘中涨幅一度超过3%。 今天A股市场有一只新股上市，为超颖电子，上午盘中该股涨幅一度超过480%。 招股资料显示，超颖电子主营业务是印制电路板的研发、生产和销售，公司产品广泛应用于汽车电子、 显示、储存、消费电子、通信等领域，产品涵盖双面板至二十六层板、HDI板、厚铜板、金属基板、高 频高速板等。 招股资料称，截至报告期期末，公司共取得14项发明专利和85项实用新型专利。经过多年的发展，公司 获得"湖北省支柱产业细分领域隐形冠军培育企业""湖北省智能制造示范单位""湖北省级重点项目""江 ...

科技股大涨。 A股市场今天（10月24日）上午整体进一步上行，其中上证指数盘中再创近10年新高，创业板指、科创50指数走势强劲。盘面 上，科技股整体大涨，成为上午市场最大亮点之一。 热点个股方面，被一些网民称为"易中天""纪连海"的几只典型热门股再度上行。 沪指盘中再创近10年新高 行业板块和赛道方面，芯片股整体大涨，芯片概念指数盘中涨幅一度超过3%，江波龙、华虹公司、神工股份、聚辰股份等多股盘 中涨幅一度超过10%。 国防军工、电力设备、汽车等板块涨幅也居于前列；煤炭、石油石化等板块上午盘中逆势下跌。 A股市场今天上午整体进一步上行，其中上证指数盘中突破年内高点，并再创近10年新高。截至中午收盘，上证指数上涨0.42%， 深证成指上涨1.3%，创业板指上涨2.09%，科创50指数上涨2.98%。 科创板表现抢眼，表征科创板表现的科创50指数大涨，盘中涨幅一度超过3%。 热点个股方面 ，被一些网民称为"易中天""纪连海"的几只典型热门股再度上行，其中，中际旭创涨超6%股价再创历史新高，新易 盛涨超4%，天孚通信涨超3%，寒武纪-U涨超3%，工业富联涨近4%，海光信息涨超3%。 新股超颖电子盘中一度大涨逾480 ...

科技股大涨。 A股市场今天（10月24日）上午整体进一步上行，其中上证指数盘中再创近10年新高，创业板指、科创50指数走势强劲。盘面上，科技股整体大涨，成为上 午市场最大亮点之一。 热点个股方面，被一些网民称为"易中天""纪连海"的几只典型热门股再度上行。 沪指盘中再创近10年新高 A股市场今天上午整体进一步上行，其中上证指数盘中突破年内高点，并再创近10年新高。截至中午收盘，上证指数上涨0.42%，深证成指上涨1.3%，创业 板指上涨2.09%，科创50指数上涨2.98%。 科创板表现抢眼，表征科创板表现的科创50指数大涨，盘中涨幅一度超过3%。 新股超颖电子盘中一度大涨逾480% 今天A股市场有一只新股上市，为超颖电子，上午盘中该股涨幅一度超过480%。 招股资料显示，超颖电子主营业务是印制电路板的研发、生产和销售，公司产品广泛应用于汽车电子、显示、储存、消费电子、通信等领域，产品涵盖双面 板至二十六层板、HDI板、厚铜板、金属基板、高频高速板等。 招股资料称，截至报告期期末，公司共取得14项发明专利和85项实用新型专利。经过多年的发展，公司获得"湖北省支柱产业细分领域隐形冠军培育企业""湖 北省智能制造 ...

Group 1 - The Hang Seng Index rebounded, closing up 0.72%, with the internet sector leading the gains, followed by banking, industry, technology, and real estate sectors [1] - The internet sector saw a rise of 1.07%, with Meituan up 4.06%, Alibaba up 1.67%, Tencent Holdings up 1.52%, JD Group up 1.5%, and Baidu Group up 1.22%. However, companies like SenseTime, Bilibili, and Kingdee International experienced declines [3] - The banking sector opened strong and maintained a consolidation above the midline, closing up 0.88%, with Postal Savings Bank rising 4.59% and Minsheng Bank up 2.39% [3] Group 2 - The consumer sector rebounded, closing up 0.35%, with notable gains from companies like Chenzi Biological up 6.68%, Li Ning up 6.55%, and Sands China up 4.4% [3] - The healthcare sector opened low and saw a slight reversal near the end, closing down 1.31%, with CSPC Pharmaceutical down 2.96% and China Biopharmaceutical down 2.78% [3]

Core Insights - The report highlights the strong performance of Chinese pharmaceutical companies at the ESMO conference, suggesting that Q4 2025 will see increased focus on policies, academic conferences, and business development catalysts [1][2] - The Hang Seng Healthcare Index rose by 2.0% this week, underperforming the broader market, with CXO, internet pharmaceuticals, and biopharmaceuticals showing better performance [1] - Institutional holdings in the pharmaceutical sector have seen fluctuations, with a slight decrease in domestic holdings through the Hong Kong Stock Connect, while foreign investments have also been declining since mid-year [1] Market Review - The report notes that since October, the pharmaceutical sector has experienced significant price volatility, but the overall trend remains focused on innovative drug investments, particularly in companies with clear pipeline values and cost-effectiveness [1][2] - Key companies such as Kangfang Biotech, Rongchang Biotech, Kelun-Botai, and others presented significant data at the ESMO conference, indicating a potential market revival as industry catalysts increase [2] Investment Recommendations - The report recommends focusing on innovative drugs, particularly companies like 3SBio and DQ Pharma, which have rich short-term catalysts and whose valuations do not yet reflect the value of their core products [2] - It also suggests that CXO companies, benefiting from high downstream demand and improving financing conditions, should be prioritized, with WuXi AppTec highlighted as a leading player in this segment [2]

Core Viewpoint - *ST Jingfeng's stock reached the daily limit with a price of 7.05 yuan, reflecting a 5.02% increase, driven by restructuring progress, debt waiver, and successful bids in centralized procurement [1][2]. Company Summary - The company is currently in a transitional phase of restructuring, with Shiyao Group confirmed as the lead investor and a restructuring investment agreement signed, providing hope for the company's future [2]. - Five fund managers waived 110 million yuan in principal and related fees, significantly reducing the company's debt burden, which has boosted market confidence in its future development [2]. - The sale of the "Taihu Star" asset recovered 64.6928 million yuan, helping to optimize the asset structure by divesting loss-making subsidiaries [2]. - The company has successfully won bids for products like sodium hyaluronate injection in several provincial alliances, which is expected to expand market share and improve performance [2]. - In the first half of 2025, the company maintained a certain level of R&D investment and received government subsidies, providing support for its performance [2]. Industry Summary - The pharmaceutical industry has recently attracted market attention, with several stocks in the sector performing actively on October 24, 2025, contributing to *ST Jingfeng's stock limit-up [2]. - Technical indicators suggest that if the MACD forms a golden cross, it could further support the stock price's upward movement [2]. - There may have been capital inflows on the day of the stock limit-up, and it is important to monitor whether this trend continues [2].

Group 1 - The U.S. is increasing pressure on Venezuela, with Trump seeking land action under the pretext of drug issues [2] - The U.S. has deployed B-1 bombers near Venezuela, heightening geopolitical risks and stimulating demand for safe-haven assets [2] - International oil prices surged to two-week highs due to U.S. sanctions on two major Russian oil companies, with WTI crude reaching $61.74 per barrel, up 3.99%, and Brent crude rising 5.38% to $65.90 per barrel [2][5] Group 2 - U.S. stock indices showed positive performance, with the Dow Jones up 0.3%, S&P 500 up 0.58%, and Nasdaq up 0.89% [3] - Quantum computing stocks saw significant gains, with IonQ rising 7%, Quantum up nearly 10%, and D-Wave up nearly 14% [3] - The Nasdaq Golden Dragon China Index increased by 1.6%, with Alibaba rising 3.6% [3] Group 3 - Hong Kong's Hang Seng Index closed up 0.72% at 25,967.98 points, with a trading volume of HKD 245.256 billion [4] - The A-share market experienced fluctuations, with the Shanghai Composite Index gaining 0.22% and the Shenzhen Component Index also up 0.22% [4] Group 4 - Gold prices rose by 0.66% to $4,125.19 per ounce, while silver increased by 0.86% to $48.85 per ounce [5] - Bitcoin reached $109,656, up 1.92%, and Ethereum rose to $3,832.7, up 2.35% [6]

Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The report emphasizes the significance of the ESMO conference, highlighting the achievements of Chinese pharmaceutical companies and suggesting to focus on catalysts such as policies, academic conferences, and business development in Q4 2025 [1][4] - The report indicates a potential market rebound due to increasing industry catalysts, including various academic conferences and favorable policies [4] - The report recommends continued attention to companies with promising clinical pipelines and their global commercialization potential [4][5] Valuation Summary - The report provides a detailed valuation overview of various companies, with all covered companies rated as "Buy" except for two rated as "Neutral" and one as "Sell" [3] - Notable target prices and current prices for selected companies include: - AstraZeneca: Target price 93.30, Current price 83.87 [3] - BeiGene: Target price 225.00, Current price 188.20 [3] - Innovent Biologics: Target price 48.00, Current price 36.42 [3] - I-Mab: Target price 105.00, Current price 86.10 [3] - China Biologic Products: Target price 9.10, Current price 7.43 [3] Market Performance - The Hang Seng Index rose by 2.3% and the Hang Seng Healthcare Index increased by 2.0% during the week of October 14-21, 2025, ranking fifth among twelve industry indices [4][7] - Sub-industry performance showed CXO leading with a 4.5% increase, followed by Internet medicine and biopharmaceuticals [4][7] Institutional Holdings - As of October 21, 2025, the proportion of domestic institutional holdings through Hong Kong Stock Connect decreased slightly to 22.1%, while foreign institutional holdings also saw a minor decline to 38.6% [34][38] - The report notes that both domestic and foreign investors are increasing their positions in innovative drug companies with clear pipeline values [4][38] Clinical Developments - The report highlights significant clinical trial results presented at the ESMO conference, including: - CanSino Biologics' promising data on its PD-1/VEGF inhibitor [5][6] - Rongchang Biopharmaceuticals' HER2 ADC showing significant survival benefits [5][6] - Kelun-Biotech's results indicating substantial improvements in progression-free survival [5][6] - The report suggests that these developments enhance the global competitiveness of the covered companies [5][6]

Market Overview - Hong Kong stocks rebounded after hitting a low, with the Hang Seng Index closing up 0.72% at 25,967.98 points and a total turnover of HKD 2,452.56 million [1] - The Hang Seng Tech Index rose 0.48%, indicating a positive sentiment in the tech sector, particularly benefiting from AI narratives [1] Blue-Chip Stocks Performance - Meituan-W (03690) saw a significant increase of 4.06%, closing at HKD 100, contributing 33.69 points to the Hang Seng Index [2] - Li Ning (02331) rose 6.55% to HKD 18.54, contributing 4.22 points to the index [2] - China Hongqiao (01378) increased by 4.48% to HKD 26.58, contributing 4.97 points [2] - China National Offshore Oil Corporation (00883) rose 2.15% to HKD 19.92, contributing 10.27 points [2] Sector Highlights Banking Sector - Major banks continued to rise, with Postal Savings Bank (01658) up 4.59% and Agricultural Bank (01288) up 1.88% [3] - The banking sector is expected to show stable performance with a resilient operating environment, as the third-quarter reports are anticipated to reflect steady revenue growth [3] Oil Sector - The "Big Three" oil companies were active, with CNOOC (00883) up 2.15% and Sinopec (00386) up 1.69% [4] - International oil prices rose significantly, with WTI crude oil up 2.20% to USD 58.50 per barrel, driven by geopolitical tensions and sanctions on Russian oil companies [4] Lithium Sector - Lithium stocks surged, with Ganfeng Lithium (01772) up 8% and Tianqi Lithium (09696) up 5.1% [4] - The price of lithium carbonate futures rose over 4%, indicating strong demand from the electric vehicle and energy storage markets [5] Pharmaceutical Sector - Pharmaceutical stocks faced pressure, with Rongchang Bio (09995) down 10.93% and Innovent Biologics (01877) down 3.95% [6] - The sector's underperformance is attributed to tariff impacts and slower-than-expected external licensing developments [6] Notable Stock Movements - Giant Bio (02367) rebounded significantly, closing up 6.68% after receiving a medical device registration certificate [7] - Li Ning (02331) announced its entry into Meituan's flash purchase platform, enhancing its distribution capabilities [8] - Sands China (01928) reported a 7.5% year-on-year increase in net revenue for Q3, closing up 4.4% [9] - Dreamland (01119) saw a 4.31% increase after launching a new mobile game that topped various app store charts [10]